A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to produce defence proteins, which are then passed to the foetus through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% protection when immunised 4 weeks before birth
- Maternal antibodies transferred through the placenta safeguard newborns from day one
- Coverage achievable with two-week gap before early delivery
- Vaccination during the third trimester still offers significant infant protection
Persuasive evidence from recent research
The performance of the pregnancy RSV vaccine has been demonstrated through a thorough investigation conducted across England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing strong and reliable evidence of the vaccine’s real-world impact. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The scope of this study offers healthcare professionals and prospective parents with trust in the vaccine’s established performance across varied populations and settings.
The results paint a notable picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s critical role in reducing the risk of serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research analysed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection rates and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically significant and indicative of the general population, rather than individual cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology assessed actual clinical results rather than experimental conditions, providing real-world data of how the vaccine functions when given across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its risks
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it extremely challenging for affected infants to feed and breathe properly. Parents frequently observe their babies fighting for breath, their chests rising whilst they attempt to draw sufficient oxygen into their weakened respiratory system. Whilst most infants improve through palliative treatment, a limited though important group succumb from RSV complications yearly, making prevention through vaccination a critical public health priority for protecting the most vulnerable and youngest people in our communities.
- RSV produces inflammation in lungs, leading to serious respiratory problems in babies
- Nearly 50% of infants contract the virus during their first few months alive
- Symptoms range from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies die from RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have emphasised the significance of pregnant women getting their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that the timing is essential for ensuring newborns receive the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery provides nearly 85% protection, experts recommend women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies via the placenta.
The guidance from health authorities remains clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among eligible pregnant women, whilst others remain focused to boost understanding and access to the jab. These geographical variations reflect differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the overall statistics shows robust and reliable protection irrespective of geographical location.
- NHS trusts rolling out multiple messaging strategies to connect with pregnant women
- Geographic variations in vaccine uptake rates throughout England require targeted improvement
- Community health services modifying schemes to suit community needs and circumstances
Practical implications and parental perspectives
The vaccine’s outstanding effectiveness provides tangible benefits for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the launch of this preventative solution, the 80% drop in admissions equates to thousands of infants shielded from severe infection. Parents no longer face the upsetting situation of watching their newborns labour to breathe or labour to feed, symptoms that mark critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal breathing health, giving expectant mothers a active means to safeguard their most vulnerable children during those critical early months.
For families like that of Malachi, whose acute RSV infection led to severe brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s advocacy for the jab emphasises the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers in their late pregnancy, changing what was once an predictable seasonal threat into a manageable health risk.